[{"id":"de421412-fb86-418c-a6aa-0a09654defc6","acronym":"DSP-5336-101","url":"https://clinicaltrials.gov/study/NCT04988555","created_at":"2021-08-03T18:53:07.117Z","updated_at":"2024-07-02T16:35:23.111Z","phase":"Phase 1/2","brief_title":"A Study of DSP-5336 in Relapsed/Refractory AML/ ALL With or Without MLL Rearrangement or NPM1 Mutation","source_id_and_acronym":"NCT04988555 - DSP-5336-101","lead_sponsor":"Sumitomo Pharma America, Inc.","biomarkers":" FLT3 • IDH1 • IDH2 • NPM1 • KMT2A","pipe":" | ","alterations":" NPM1 mutation • MLL fusion","tags":["FLT3 • IDH1 • IDH2 • NPM1 • KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation • MLL fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e enzomenib (DSP-5336) • Noxafil (posaconazole)"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 02/28/2022","start_date":" 02/28/2022","primary_txt":" Primary completion: 01/02/2025","primary_completion_date":" 01/02/2025","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2024-01-18"},{"id":"55adb811-b891-4933-bcb8-86892c74e47f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04752163","created_at":"2021-02-12T13:55:51.280Z","updated_at":"2024-07-02T16:35:29.212Z","phase":"Phase 1/2","brief_title":"DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT04752163","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" FLT3 • NPM1","pipe":" | ","alterations":" NPM1 mutation","tags":["FLT3 • NPM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Rituxan (rituximab) • cytarabine • azacitidine • cyclophosphamide • methotrexate • vincristine • leucovorin calcium • Truxima (rituximab-abbs) • emilumenib succinate (DS-1594) • mesna • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Neupogen (filgrastim) • Novex (rituximab biosimilar) • Noxafil (posaconazole) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 03/25/2021","start_date":" 03/25/2021","primary_txt":" Primary completion: 11/08/2023","primary_completion_date":" 11/08/2023","study_txt":" Completion: 11/08/2023","study_completion_date":" 11/08/2023","last_update_posted":"2023-11-15"},{"id":"6c975a09-ad7a-4753-bf03-1fb9ba24377a","acronym":"Posa-Pk","url":"https://clinicaltrials.gov/study/NCT03796533","created_at":"2023-06-15T19:08:12.630Z","updated_at":"2024-07-02T16:36:16.640Z","phase":"","brief_title":"Pharmacokinetics Variability of Posaconazole (PCZ) and Its Glucuronide Metabolite During Induction and Consolidation Treatments in Patients With Acute Myeloid Leukemia (AML): a Covariate Analysis With the Tablets Formulation and Evaluation of the Potential Risk of Hepatotoxicity","source_id_and_acronym":"NCT03796533 - Posa-Pk","lead_sponsor":"Hospices Civils de Lyon","biomarkers":" UGT1A4","pipe":"","alterations":" ","tags":["UGT1A4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Noxafil (posaconazole)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 12/10/2018","start_date":" 12/10/2018","primary_txt":" Primary completion: 04/10/2023","primary_completion_date":" 04/10/2023","study_txt":" Completion: 04/10/2023","study_completion_date":" 04/10/2023","last_update_posted":"2022-02-24"},{"id":"73ea380b-7de2-400a-b9ef-31fcae769d41","acronym":"","url":"https://clinicaltrials.gov/study/NCT04725942","created_at":"2023-06-15T19:08:12.849Z","updated_at":"2024-07-02T16:36:35.479Z","phase":"","brief_title":"Posaconazole for Pulmonary Fungal Infection Prophylaxis in Hematopoietic Stem Cell Transplantation Patients","source_id_and_acronym":"NCT04725942","lead_sponsor":"Institute of Hematology \u0026 Blood Diseases Hospital","biomarkers":" UGT1A4","pipe":"","alterations":" ","tags":["UGT1A4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Noxafil (posaconazole)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 360","initiation":"Initiation: 01/01/2021","start_date":" 01/01/2021","primary_txt":" Primary completion: 04/01/2023","primary_completion_date":" 04/01/2023","study_txt":" Completion: 04/01/2023","study_completion_date":" 04/01/2023","last_update_posted":"2021-01-27"},{"id":"ce98ee02-21d8-47cc-adbf-beb7c12bd1ab","acronym":"","url":"https://clinicaltrials.gov/study/NCT03760445","created_at":"2021-01-18T18:28:53.713Z","updated_at":"2024-07-02T16:36:51.542Z","phase":"Phase 1/2","brief_title":"HDM201 Added to CT in R/R or Newly Diagnosed AML","source_id_and_acronym":"NCT03760445","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" FLT3 • PML","pipe":" | ","alterations":" FLT3 mutation","tags":["FLT3 • PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e midostaurin • Vyxeos (cytarabine/daunorubicin liposomal formulation) • idarubicin hydrochloride • siremadlin (HDM201) • Noxafil (posaconazole) • midazolam hydrochloride"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 11/15/2019","start_date":" 11/15/2019","primary_txt":" Primary completion: 07/22/2021","primary_completion_date":" 07/22/2021","study_txt":" Completion: 06/13/2023","study_completion_date":" 06/13/2023","last_update_posted":"2020-01-09"}]